Successful transfemoral core valve aortic valve implantation in a patient with degenerated solofreedom biologic supravalvular aortic valve

Abstract

Prikaz slučaja Percutaneous aoric valve implantaion (TAVI) is well established treatment opion for high risp paients with severe aoric stenosis. Transcatheter aoric valve implantaion (TAVI) is an atracive treatment opion for paients with failing bioprostheses (valve-in-valve concept), especially in elderly paients with high risk for reoperaion. Although clinical experience is sill limited for this of-label indicaion, the procedure has been shown to be feasible in stented as well as stentless bioprostheses. We report a case of of 71-years old woman were CoreValve 23 mm (Medtronic, Inc., Minneapolis, Minnesota, USA) was implanted inside a degenerated Sorin Freedom SOLO bioprosthesis using transfemoral approach. Freedom SOLO bioprosthesis stentless bioprosthesis is sutured in supra-annular posiion and presents a TAVI challenge due to its proximity to coronary osia. Careful pre-procedural planning with TEE and CTA is crucial. We decided for transfemoral approach with 23 m CoreValve implantaion. Balloon valvuloplasty before TAVI with contrast injecion may predict the inal result and is helpful for procedure success and risk reducion. The inal TAVR result was good. This case proves the ViV concept for stentless Freedom SOLO bioprosthesis.

Successful Reoperation in 3 Cases of Failed Sorin Freedom Stentless Aortic Valve Using the LivaNova Perceval Sutureless Prosthesis

“…[7][8][9] TAVI-ViV procedure has become more recently another surgical alternative for the treatment of degenerated bioprostheses, particularly in high-risk patients with associated severe comorbidities. 10,11 However, while the TAVI-VIV is nowadays a well-established procedure in cases of failed stented prostheses, the risk correlated to this technique in degenerated stentless valves, and particularly in SPF and SPF-Solo, is still elevated. The chance of coronary obstruction by the prosthetic leaflets represents the major drawback of TAVI-VIV in these patients.…”